Primary uterine non-Hodgkin's lymphoma (NHL) is an extremely rare disease. To accumulate more information on clinical data, wereport three cases of primary uterine NHLwith apparently the first demonstration of karyotypic analysis. Histological diagnosis was diffuse large B cell type in all patients. Twoof them with advanced stage showed chemoresistance and a short survival. The remaining case with early stage showed an uneventful course following operation. No commonchromosomalabnormality was detected. The therapeutic strategy for uterine NHLmight therefore be similar to that for other types of aggressive NHL, although a larger study is needed.
Introduction
Primary non-Hodgkin's lymphoma (NHL) of the uterus is a rare disease. Its occurence has been found to be less than 1% among patients with NHL (1) (2) (3) . Because of the extremely low frequency, neither its developmental mechanismsnor clinical features are clarified. Since only a few studies have shownthat uterine NHLarises mainly from thp.B cell component (4, 5) and is not etiologically based on chronic inflammation (5) , it is important to accumulate more clinical data to explore the appropriate therapeutic procedures. Wepresent three cases of primary uterine NHLwho underwent chemotherapy alone or surgical treatment followed by chemotherapy. In addition, the karyotypic findings of the tumor cells are demonstrated since there have been no reports including such findings to our knowledge. Cytogenetic alterations apparently play a crucial role in the development of several subtypes of NHLand are related to their biological behaviors. Chromosomal analyses might therefore define a novel subset of NHLwhena specific aberration is commonly detected, while translocations t (14; 18) (q32; q21) (6) Case Reports
Case1
On March 10, 1999, a 72-year-old woman visited our department complaining of abdominal pain that had developed one monthearlier. Physical examination revealed left cervical lymph node swelling (2 cm in diameter) and a fist-sized hard tumor on her lower abdomen. A swollen uterus was observed on pelvic magnetic resonance imaging (MRI) (Fig. 1A) . Increased serum lactate dehydrogenase (LDH) at 5,478 IU// and soluble interleukin 2 receptor (SIL-2R) at 2,590 U/ml were seen. Diffuse large B cell NHL(DLBCL) was diagnosed pathologically in the biopsied cervical lymph node ( Fig. 2A) International Prognostic Index (IPI) ( 10) . Standard combined chemotherapy regimen of CHOP(ll) was not effective. Meningeal invasion that generated diplopia occurred on the 30th hospital day. Salvage intravenous chemotherapies, one consisting of mitoxantrone, etoposide, carboplatin, and prednisolone ( 1 2), and the other dexamethasone, high-dose cytosine arabinoside (Ara-C), and cisplatin (1 3), were ineffective. She died of the disease progression three months after the initial presentation. Case2 A65-year-old womanwas admitted to our hospital on September 4, 1998, with a one-third decrease in urine volumethat had continued for two weeks. She also had fever elevation of more than 38°C, Several bilateral cervical lymph nodes (3 cm in diameter) and a lower abdominal hard tumor (10 cm) were palpated. Abdominal computed tomography (CT) imaging showed swelling of the uterus and paracorpal lymph nodes (Fig.   IB ). Renal dysfunction with oliguria was also present that was caused by ureteral compression by the tumor. SerumLDHwas elevated at 5,239 IU// and SIL-2R at 14,000 U/ml. Histological diagnosis of the biopsied specimen from left cervical lymph node was DLBCL (Fig. 2B) . Findings of flow cytometry and surface immunoglobulin were the same as in Case 1. Complex abnormal karyotype was disclosed, including rearrangement of chromosome 19ql3, where the BCL3 gene is located (14) ( Table 1 ). The findings of IPI parameters defined her as highintermediate risk. She was treated with standard CHOPthat resulted in a minimal response. Bone marrowinvasion and leukemic change appeared one month after the initial chemotherapy. Her disease was refractory to the second-line chemotherapies delivered similarly to those in Case 1. She died of sepsis six months after the diagnosis.
Case3
A 45-year-old woman, whose uterine cervical polyp (1 cm in diameter) was found by a routine medical check without any subjective symptoms, was diagnosed as DLBCL in the biopsied specimen (Fig. 2C ). She underwent a total hysterectomy on April 7, 1996. She was then introduced to our department for the purpose of adjuvant chemotherapy. Noswelling of lymph nodes or other organs was detected by physical or radiological examinations. The pre-operative serum levels of LDHat 272 IU/1 and SIL-2R at 216 U/ml were within the normal limits. The karyotype of the resected tumor was normal (Table 1) . Flow cytometry was not available due to insufficient material. She was classified as low risk group according to the IPI. She received six courses of CHOPand has had an uneventful course for 59 months since the operation. togenetic aberrations. Cases 1 and 2 showed unbalanced complex chromosome abnormalities that are preferentially seen in NHL.It is notable that rearrangement of chromosomeband 14q32.3 was seen in Case 1. IgH gene, rearranged by translocations in a greater part of patients with B cell NHL(9), usually enhances the expression of proto-oncogene, cell-cycle regulator, or apoptosis suppressor in the pathogenesis of NHL.Although Case 1 did not show a knowntranslocation but an addi-Primary Uterine Non-Hodgkin's Lymphoma tion of 14q32.3, IgH rearrangement also appears to play an important role in the tumorigenesis by a translocation with undetermined partner chromosome. Chromosome band 19ql 3 rearranged in Case 2 is the locus of BCL3gene. It is reported that up-regulation of the BCL3contributes to the progression of small lymphocytic lymphomaand chronic lymphocytic leukemia with a t (14; 19) (q32; ql3) (14) . The histological diagnosis in Case 2 (DLBCL)differs from above, and the role of the BCL3is not definite. Investigational application, i.e. , fluorescence in situ hybridization, or spectrokaryotyping, might provide more information disclosing cryptic or novel translocation involving 14q32.3 or 19ql3 in these cases. Combined molecular analysis, such as Soutern blotting or polymerase chain reaction, is also considered to be helpful to examine the status of these genes. Although a normal karyotype seen in Case 3 suggests a subsequent karyotypic evolution that is related to the increase of malignant potential, whether it was derived from lymphomacells or contaminated normal cells is uncertain since a normal karyotype is rarely acquired whenthe lymphomacells are contained at a high proportion in the samples ( 16) . Commonchromosomal abnormalities among the three cases were not detected, and these findings suggest no particular pathogenetic differences of uterine NHLfrom that arising from other organs. Larger series of patients with uterine NHLshould be cytogenetically or molecularly examined. The treatment has not been standardized because the evidence of the relationship between therapeutic regimens and clinical outcomes is too limited. Conventional CHOPregimen did not offer great benefit for Cases 1 and 2. Both of them had disease progression during the chemotherapies. Moreover, intensive salvage chemotherapies were incapable of inducing a remission. By contrast, a long disease-free survival has been maintained in Case 3, whose disease was diagnosed at stage I. Observations by Stroh et al and Harris et al also showed a significantly longer survival in the groups of uterine NHLwith stages I and II than in those with III and IV (3, 4) . The prognosis of primary uterine NHLmay be predicted by the values of IPI similarly to other types of aggressive NHL.Thus, refractory uterine NHLclassified as higher risk groups according to the IPI might be appropriate candidates for high-dose chemotherapy using a hematopoietic stem cell support to acquire a remission as the International Consensus Conference suggested ( 17). We did not plan an operation mainly because of poor performance status in Case 1 and renal dysfunction in Case 2. However, preceding with surgical treatment might be a choice for those whohave a bulky uterine mass to reduce the tumor burden. In fact, a beneficial effect of combination of chemotherapy, operation, and radiation according to the tumor status is described by Stroh et al (3) . To further determine whether therapeutic strategy of aggressive NHLcan also be applied to uterine DLBCL, more evidence must be evaluated. Finally, primary uterine NHLas an intrapelvic tumor is not symptomatic till it extensively grows or metastasizes. It results in the initial diagnosis made in the advanced stages, as in Cases 1 and 2. Unfortunately, routine medical check, that incidentally found early stage NHLin Case 3, has hardly detected asymptomatic uterine NHLto date (18) . The routine medical check for uterine tumors must therefore be more refined and its importance should be more strongly emphasized.
